Vertex Pharma (VRTX) Tops Q4 EPS by 24c, Revenues Beat; Offers FY19 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Vertex Pharma (VRTX) Tops Q4 EPS by 24c, Revenues Beat; Offers FY19 Revenue Guidance
February 6, 2019 7:53 AM EST
BMO Capital analyst Do Kim raised the price target on Vertex (NASDAQ: VRTX) to $234.00 (from $192.00) while maintaining a Outperform rating.
Kim commented, "Our target price rises to $234 from $192, as we increase long-term CF revenue projections, following another solid 4Q18 beat on revenues and... More
February 6, 2019 7:52 AM EST
Cowen analyst Phil Nadeau raised the price target on Vertex (NASDAQ: VRTX) to $220.00 (from $210.00) while maintaining a Outperform rating.
The analyst commented, "VRTX reported Q4 CF franchise revenue of $868.2MM vs consensus of $818.8MM, non-GAAP EPS of $1.30 vs. consensus of $1.08. 2019 revenue guidance... More
February 6, 2019 7:45 AM EST
Maxim Group analyst Jason McCarthy downgraded Vertex (NASDAQ: VRTX) from Buy to Hold.
The analyst highlighted:
Vertex reported 4Q18 with cystic fibrosis (CF) revenue of $868M, representing sequential growth of 11% and beating consensus of $816M; the results include Kalydeco revenue of $259M vs. $250.5M...
More
February 6, 2019 7:14 AM EST
RBC Capital analyst Brian Abrahams lowered the price target on Vertex (NASDAQ: VRTX) to $213.00 (from $215.00) while maintaining a Outperform rating.
...
More
February 1, 2019 8:27 AM EST
Jefferies analyst Michael Yee reiterated a Buy rating and $210 price target on Vertex (NASDAQ: VRTX) noting that on Feb 4th, the UK Parliament House of Commons is scheduled to debate whether the government should enact a "Crown Use" license rule that allows... More
